2025-08-19T11:45:42+00:00 2023-09-30 390859910 Baker Tilly Advisory Group LP 225 South 6th St Suite 2300 Minneapolis MN 55402 990 2022-10-01 411704734 NMDP FOUNDATION NMDP 7634068700 500 N 5TH ST MINNEAPOLIS MN 554011206 Katherine Heyerdahl CHIEF FINANCIAL OFFICER 2025-08-19 true Karen A Gries P00078514 6128764500 2022 2025-03-06 01:10:19Z X Erica Jensen 500 N 5TH ST MINNEAPOLIS MN 554011206 20162412 false X WWW.nmdp.org X 1991 MN RAISES FUNDS TO SUPPORT THE NATIONAL MARROW DONOR PROGRAM (NMDP) MISSION: WE SAVE LIVES THROUGH CELLULAR THERAPY. 18 17 44 3231 0 0 13066515 18893262 0 283656 350756 -548424 -555030 12801747 18688988 10956064 9700536 0 4686099 5791779 418679 612029 2149445 1716828 2157082 17777670 18261426 -4975923 427562 15501279 15913956 2624098 1878244 12877181 14035712 X See Schedule O. false false 5352583 5352583 Patient Assistance: NMDP Foundation PROVIDES FINANCIAL ASSISTANCE TO PATIENTS THROUGHOUT EACH STAGE OF THE TRANSPLANT PROCESS. FUNDED BY PHILANTHROPY, IN FY23 MORE THAN $5.3 MILLION WAS PROVIDED TO OVER 2,600 PATIENTS FROM 155 TRANSPLANT CENTERS. IN FY23 THE PROPORTION OF GRANT RECIPIENTS WHO IDENTIFIED AS NON-HISPANIC WHITE RANGED FROM 0%-65% DEPENDING ON THE GRANT TYPE. FOR THE SICKLE CELL FERTILITY PRESERVATION GRANT, WHICH HELPS PAY FOR FERTILITY PRESERVATION AND STORAGE PRE-TRANSPLANT FOR SICKLE CELL DISEASE, ALL RECIPIENTS IDENTIFIED AS EITHER BLACK, AFRICAN AMERICAN OR MULTIPLE RACE. FOR THE POST-TRANSPLANT SUPPORT ASSISTANCE (TSA) GRANT, 65% OF RECIPIENTS IDENTIFIED AS NON-HISPANIC WHITE. THE SEARCH ASSISTANCE FUND GRANT (SAF) SUPPORT PATIENTS PRE-TRANSPLANT WHO HAVE BARRIERS RELATED TO INSURANCE THAT DELAY OR PREVENT THEM FROM FINDING A DONOR OR CORD BLOOD UNIT. THIS GRANT HELPS PATIENTS START THE SEARCH FOR AN UNRELATED DONOR OR CORD BLOOD UNIT BY GIVING TRANSPLANT CENTERS A GUARANTEE OF PAYMENT FOR SPECIFIC SEARCH AND/OR PROCUREMENT COSTS SHOULD THEY NOT BE COVERED BY INSURANCE. THERE WERE 42 PATIENTS APPROVED FOR SAF IN FY23. THE SICKLE CELL FERTILITY PRESERVATION GRANT HELPS PAY FOR FERTILITY PRESERVATION AND STORAGE FEES FOR PATIENTS WITH SICKLE CELL DISEASE PREPARING FOR TRANSPLANT. THIS GRANT IS PAID TO THE FERTILITY PRESERVATION CLINIC OR PATIENT WHEN INSURANCE DOES NOT COVER THIS COST. IN FY23, THIS GRANT WAS DISTRIBUTED TO 19 PATIENTS WITH AN AVERAGE AWARD AMOUNT OF $5,468. NATIONAL MARROW DONOR PROGRAM (NMDP) ALSO PROVIDES FUNDING TO HELP WITH THE MANY UNCOVERED OUT-OF-POCKET EXPENSES FOR PATIENTS BEFORE AND AFTER TRANSPLANT. THE TSA GRANT PROVIDES DIRECT FINANCIAL ASSISTANCE TO QUALIFIED FAMILIES BOTH PRE- AND POST-TRANSPLANT. TSA HELPS WITH EXPENSES SUCH AS TRANSPORTATION, TEMPORARY RELOCATION, COPAYS AND INSURANCE PREMIUMS. IN FY23, 2,549 TSA AWARDS WERE GRANTED TO 2,096 PATIENTS PRE- AND POST-TRANSPLANT WITH THE AVERAGE AWARD BEING $1,500. THE JOHN AND CARYN CAMIOLO SURVIVORSHIP GRANT (CAM) PROVIDES DIRECT FINANCIAL ASSISTANCE TO ELIGIBLE PATIENTS, WHO ARE AT LEAST THREE MONTHS POST-TRANSPLANT AND WHO ARE ACTIVELY RECEIVING TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE. CAM HELPS WITH UNCOVERED COSTS OF TREATMENT AND PRESCRIPTIONS. IN FY23, 218 PATIENTS WERE HELPED THROUGH THE CAM GRANT WITH EACH PATIENT AWARDED $750. THE CHELL TRAVEL GRANT PROVIDES DIRECT FINANCIAL ASSISTANCE TO ELIGIBLE PATIENTS WHO NEEDED ASSISTANCE WITH TRAVEL COSTS TO PARTICIPATE IN CLINICAL TRIALS THAT TREAT BLOOD CANCERS OR BLOOD DISORDERS. FOR THIS GRANT, 51% OF RECIPIENTS IDENTIFIED AS NON-HISPANIC WHITE. IN FY23, 176 PATIENTS RECEIVED THE CHELL TRAVEL GRANT WITH THE AVERAGE AWARD AMOUNT BEING $2,149. TWO CRISIS GRANTS HELP PATIENTS EXPERIENCING A SIGNIFICANT CRISIS EVENT IMPACTING ACCESS TO TRANSPLANT OR POST-TRANSPLANT CARE. THE IRA AND DIANA RIKLIS CRISIS GRANT PROVIDES UP TO $10,000 IN DIRECT FINANCIAL ASSISTANCE TO QUALIFIED PATIENTS POST-TRANSPLANT AND THE MAKE ME STRONGER CRISIS GRANT PROVIDES UP TO $15,000 PRE-TRANSPLANT. IN FY23, 28 PATIENTS WERE HELPED THROUGH THESE CRISIS GRANTS WITH THE AVERAGE AWARD AMOUNT BEING $8,182. A COMMITTEE OF BMT SOCIAL WORKERS AND NAVIGATORS REVIEWS EACH CRISIS APPLICATION TO ENSURE EQUITABLE DISTRIBUTION OF THIS GRANT. IN FY23, 59% OF GRANT RECIPIENTS IDENTIFIED AS NON-HISPANIC WHITE. 2023876 2023876 RESEARCH: RESEARCH INNOVATIONS ARE CRITICAL TO EXPANDING TREATMENT TO MORE PATIENTS AND IMPROVING OUTCOMES. EACH YEAR, NMDP Foundation IS PROUD TO INVEST IN RESEARCH THROUGH: THE NMDP AMY STRELZER MANASEVIT RESEARCH PROGRAM (AMY RESEARCH PROGRAM): OUR FLAGSHIP RESEARCH FELLOWSHIP, THE AMY PROGRAM FUNDS EARLY CAREER INVESTIGATORS FOCUSED ON ADVANCES IN THE PREVENTION AND TREATMENT OF POST-CELL THERAPY COMPLICATIONS (E.G., GRAFT-VERSUS-HOST-DISEASE AND INFECTION). IN 2023, WE FUNDED THE WORK OF 12 AMY SCHOLARS. AMY SCHOLARS HAVE GONE ON TO BECOME LEADERS IN THE FIELD, PURSUING SCIENTIFIC ADVANCES THAT HELP NMDP PATIENTS LIVE LONGER, HEALTHIER LIVES. SINCE 1998, NMDP Foundation HAS INVESTED NEARLY $12.5 MILLION TO HELP LAUNCH THE CAREERS OF 49 YOUNG PHYSICIAN-SCIENTISTS. After receiving their NMDP Amy Scholar Award, 49 young physician-scientists have gone on to win more than $250 million in subsequent government grant funding to pursue the discoveries to help patients live longer, healthier lives after cell therapy. TODAY, THE AMY STRELZER MANASEVIT RESEARCH PROGRAM FOR THE STUDY OF POST-CELL THERAPY COMPLICATIONS IS ONE OF THE LARGEST AND MOST COVETED FELLOWSHIPS IN THE FIELD OF TRANSPLANTATION. DONOR FOR ALL: THIS SERIES OF TRANSFORMATIONAL MULTI-CENTER STUDIES ARE TESTING A NEW TRANSPLANT PROTOCOL AIMED AT MAKING MISMATCHED DONOR TRANSPLANTS SAFER AND MORE EFFECTIVE, WITH THE GOAL OF EXPANDING ACCESS TO TRANSPLANT TO THOUSANDS OF PATIENTS WHO LACK A FULLY MATCHED DONOR. ANTHONY NOLAN TRUST: PROVIDE SUPPORT TO THE ANTHONY NOLAN RESEARCH INSTITUTE TO CONTINUE DEVELOPMENT AND MAINTENANCE OF AN HLA CLASS I AND II SEQUENCE DATABASE AND PROVISION OF HLA CLASS I AND II SEQUENCE INFORMATION. NMDP'S CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH (CIBMTR)- A PARTNERSHIP WITH THE MEDICAL COLLEGE OF WISCONSIN IS THE LEADING HUB FOR TRANSPLANT AND CELL THERAPY RESEARCH. NMDP FOUNDATION HELPS TO FUND VARIOUS OTHER INNOVATIVE RESEARCH STUDIES LED AND MANAGED BY THE CIBMTR. 676771 676771 Recruitment: THE NMDP REGISTRY IS THE MOST DIVERSE LISTING OF POTENTIAL DONORS AND CORD BLOOD UNITS IN THE WORLD. EVERY SEARCH THROUGH NMDP PROVIDES PATIENTS WITH ACCESS TO MORE THAN 41 MILLION POTENTIAL ADULT DONORS AND MORE THAN 800,000 CORD BLOOD UNITS WORLDWIDE. THE BEST MATCH FOR A PATIENT IS TYPICALLY SOMEONE WHO SHARES THEIR ETHNIC BACKGROUND. IMPROVING THE ETHNIC DIVERSITY OF THE NMDP REGISTRY IMPROVES ALL PATIENTS' ODDS OF FINDING THEIR BEST MATCH, REGARDLESS OF ETHNIC BACKGROUND. PEOPLE BETWEEN THE AGES OF 18 AND 35 ARE MOST URGENTLY NEEDED. RESEARCH HAS SHOWN THAT CELLS FORM YOUNGER DONORS LEAD TO BETTER LONG-TERM SURVIVAL FOR PATIENTS. IN FY23, MORE THAN 330,000 POTENTIAL DONORS JOINED THE NMDP REGISTRY AND MORE THAN 4,200 UMBILICAL CORD UNITS WERE ADDED TO THE REGISTRY. 7133754 1647306 NMDP FOUNDATION PARTNERS WITH NMDP TO ADVANCE VARIOUS INITIATIVES TIED TO THE SHARED MISSION. THESE PROGRAMS INCLUDE: NMDP PROVIDES COMPREHENSIVE EDUCATION AND SUPPORT SERVICES TO PATIENTS AND THEIR FAMILIES THROUGH ONE-ON-ONE NAVIGATION SUPPORT, VIDEO, PRINTED, AND DIGITAL EDUCATION RESOURCES, COUNSELING, NMDP PEER CONNECT PROGRAM, NMDP SURVIVORSHIP PROGRAM, NMDP SICKLE CELL WARRIOR PROGRAM, AND THE JASON CARTER CLINICAL TRIALS SEARCH AND SUPPORT PROGRAM, WHICH HELPS PATIENTS WITH LIFE-THREATENING BLOOD DISORDERS FIND CLINICAL TRIALS. NMDP Foundation RAISES FUNDS TO SUPPORT THESE CRITICAL SERVICES. NMDP ALLOCATES COMPENSATION AND BENEFITS AND OCCUPANCY COSTS TO PROGRAMS BASED ON EMPLOYEE RESPONSIBILITIES. 7133754 1647306 15186984 true true false false false false false false true false false false false false true false true false false true true true true true true false true true true false false false false false false false false true false false false false true false false false true X 267 0 true 44 true false true MX false false false true true false false false false false false X 18 17 false false true false true true true true true false false true true true true true true true true false CA FL GA AL HI IL KS KY MD MA MI MN MS NH NJ NM NY NC OR PA RI SC TN UT VA AR WV WI X X Katherine Heyerdahl 7634064275 500 N 5TH ST MINNEAPOLIS MN 554011206 AMY RONNEBERG Chief Executive Officer 2.0 48.0 X X 0 1487126 250684 DIANA CARTER TREASURER 1.0 0 X X 0 0 0 MELISSA KONG VICE CHAIR 1.0 0 X X 0 0 0 MICHAEL STEWART CHAIR 1.0 0 X X 0 0 0 ANDREW BLOCK DIRECTOR 1.0 0 X 0 0 0 ANNIE BALLANTINE DIRECTOR 1.0 0 X 0 0 0 BRUCE MANASEVIT DIRECTOR 1.0 0 X 0 0 0 DERYN POMEROY DIRECTOR 1.0 0 X 0 0 0 DIANNA CERVANTES DIRECTOR 1.0 0 X 0 0 0 GUSTAVO ALCOCER DIRECTOR 1.0 0 X 0 0 0 JASON AHLGREN DIRECTOR 1.0 0 X 0 0 0 JOHN PRESLEY DIRECTOR 1.0 0 X 0 0 0 RAMESH SUBRAHMANIAN DIRECTOR 1.0 0 X 0 0 0 RAYNE ROUCE DIRECTOR 1.0 0 X 0 0 0 REBECCA WENNGATZ DIRECTOR 1.0 0 X 0 0 0 RENE SIGMAN DIRECTOR 1.0 0 X 0 0 0 SARAH ASMA DIRECTOR 1.0 0 X 0 0 0 THOMAS TEACH DIRECTOR 1.0 0 X 0 0 0 KRISTA DUSIL CHIEF FINANCIAL OFFICER 1.0 49.0 X 0 565014 78917 Joy King CHIEF ADVANCEMENT OFFICER 20.0 30.0 X 225301 337951 113604 Alex Mensing DIRECTOR, BENEFACTOR ENGAGEMENT & MARKETING 50.0 0 X 159143 0 41880 Angie Fitzgerald SENIOR DIRECTOR, CORPORATE PARTNERSHIPS 50.0 0 X 186750 0 56155 Daniel LEE DIRECTOR, MAJOR AND PLANNED GIFTS 50.0 0 X 159879 0 45849 Jacqueline Chandonnet DIRECTOR, DEVELOPMENT 50.0 0 X 160978 0 21552 Todd Peterson VICE PRESIDENT, ADVANCEMENT 50.0 0 X 231198 0 65816 gina graves former officer 0.0 0.0 X 0 358453 36354 jeffrey chell former officer 0.0 0.0 X 0 100002 0 1123249 2848546 710811 13 true true false STREAMWORKS 3640 PHEASANT RIDGE DRIVE NORTHEAST BLAINE MN 55449 CREATIVE, PRINT & MAIL SERVICES 606754 BLACKBAUD PO BOX 930256 ATLANTA GA 31193 SOFTWARE SUPPORT 269976 ALLEGIANCE FUNDRAISING GROUP PO 9132 FARGO ND 581069132 FUNDRAISING SUPPORT 137577 Creative Cirlce LLC 5900 WILSHIRE BOULEVARD 11TH FLOOR Los Angeles CA 90036 Talent Agency for Contract Work 126354 MMS USA INVESTMENTS INC dba EPSILON AGENCY LLC 35 WEST WACKER DRIVE CHICAGO IL 60601 Fundraising and Media Buying support 114120 5 2095070 6215736 10582456 361740 18893262 0 0 0 0 0 283513 283513 0 0 786280 719037 67243 0 67243 67243 164006 2095070 749103 -585097 -585097 35610 5284 30326 30326 FOREIGN CURRENCY GAIN/LOSS 900099 -259 -259 0 0 0 0 -259 18688988 0 0 -204274 4421620 4421620 5249280 5249280 29636 29636 233781 165507 26540 41734 4318166 3057074 490215 770877 285817 202346 32447 51024 613016 433989 69592 109435 340999 241412 38712 60875 25000 25000 612029 612029 13599 13599 1007661 775899 20153 211609 66092 66092 399419 143791 23965 231663 3658 2817 73 768 156485 110784 17765 27936 375591 274181 90142 11268 15981 15981 RECOGNITION 34875 12556 2092 20227 REGISTRATIONS/MEMBERSHIP 58721 58721 0 0 0 0 18261426 15186984 924997 2149445 1771547 1415756 3374111 3247472 190388 1561 0 0 0 0 75054 130150 0 0 0 0 10090179 11119017 0 0 0 0 15501279 15913956 2624098 1878244 0 0 0 0 2624098 1878244 X 5784204 4107242 7092977 9928470 12877181 14035712 15501279 15913956 X 427562 770969 -40000 X false true X true false X 10751245 18034650 20737956 13066515 18893262 81483628 0 0 10751245 18034650 20737956 13066515 18893262 81483628 27125077 54358551 247043 238703 260691 293611 283513 1323561 0 0 0 3 -70 -259 -326 82806863 -911062 0.6564 0.673 X Schedule A, Part II, Line 10 Other Income DESCRIPTION - FOREIGN CURRENCY GAIN/LOSS, COLUMN A - 0.0, COLUMN B - 0.0, COLUMN C - 3.0, COLUMN D - -70.0, COLUMN E - -259.0, COLUMN F - -326.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 4542124 19605 444680 180000 5486 4820923 5550447 465 -832236 172000 4552 4542124 5098748 60000 554109 160000 2410 5550447 4612433 200500 285815 5098748 1407960 2963973 240500 4612433 0.6293 0.3707 0.0 false false 0 X 21340745 770969 1140000 754387 2665356 18675389 13599 0 13599 18688988 20182214 1140000 794387 1934387 18247827 13599 0 13599 18261426 Schedule D, Part V, Line 4 Intended uses of endowment funds THE INTENDED USES OF THE ENDOWMENT FUNDS ARE TO SUPPORT RESEARCH AND PATIENT ASSISTANCE GRANTS. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote ORGANIZATION'S LIABILITY FOR UNCERTAIN TAX POSITIONS UNDER ASC 740 THE INTERNAL REVENUE SERVICE HAS DETERMINED THAT THE PROGRAM AND NMDP Foundation ARE TAX-EXEMPT ORGANIZATIONS UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. THE NOT-FOR-PROFIT STATUS OF THE PROGRAM AND NMDP Foundation ARE CONSIDERED TAX POSITIONS UNDER FASB ASC 740, INCOME TAXES. THE ORGANIZATION FOLLOWS THE ACCOUNTING STANDARDS FOR CONTINGENCIES IN EVALUATING UNCERTAIN TAX POSITIONS. THIS GUIDANCE PRESCRIBES RECOGNITION THRESHOLD PRINCIPLES FOR THE FINANCIAL STATEMENT RECOGNITION OF TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN ON A TAX RETURN THAT ARE NOT CERTAIN TO BE REALIZED. NO LIABILITY HAS BEEN RECOGNIZED BY THE ORGANIZATION FOR UNCERTAIN TAX POSITIONS AS OF SEPTEMBER 30, 2023 OR 2022. THE ORGANIZATION'S TAX RETURNS ARE SUBJECT TO REVIEW AND EXAMINATION BY FEDERAL AND STATE AUTHORITIES. Schedule D, Part XI, Line 2(d) Other revenues in audited financial statements not in form 990 direct fundraising event and gaming expenses - 754387 Schedule D, Part XII, Line 2(d) Other expenses in audited financial statements not in form 990 direct fundraising event and gaming expenses - 754387 bad debt allowance - 40000 true Europe (Including Iceland and Greenland) 0 0 Grantmaking Other Program Services - Bone Marrow/ Stem Cell Donor Assistance 17000 North America (Canada & Mexico only) 0 0 Grantmaking Other Program Services - Bone Marrow/ Stem Cell Donor Assistance 12636 0 0 0 0 0 0 29636 0 29636 Europe (Including Iceland and Greenland) RESEARCH/SCHOLAR 17000 CHECK/WIRE 1 0 BONE MARROW / STEM CELL DONOR ASSISTANCE North America (Canada & Mexico only) 13 6997 CHECK / WIRE PATIENT GRANT North America (Canada & Mexico only) 1 5639 CHECK / WIRE false false true false false false Schedule F, Part I, Line 2 Procedures for monitoring use of grant funds THE GRANT PROVIDED TO NORTH AMERICA INCLUDES GRANTS TO MEXICO IS PART OF A BONE MARROW/ STEM CELL DONOR ASSISTANCE PROGRAM THAT IS A LONG STANDING PROGRAM THAT PROVIDES ASSISTANCE WHEN AN EMPLOYER DOES NOT COVER WAGES WHEN A DONOR IS MAKING A DONATION. THE GRANTEES ARE REQUIRED TO SUBMIT AN EMPLOYER LETTER, OR A PAY STUB TO DEMONSTRATE THAT LOST WAGES. A NMDP REPRESENTATIVE COMPLETES THE APPLICATION ON BEHALF OF THE DONOR. AN INTERNAL TEAM REVIEWS ALL APPLICATIONS AND SUPPORTING DOCUMENTS. THE OTHER GRANT TO NORTH AMERICA IS PART OF NMDP PATIENT FINANCIAL ASSISTANCE PROGRAM. GRANTS ARE MONITORED BY THE PATIENT SERVICES TEAM TO APPLICANTS BASED ON FINANCIAL NEED. NMDP EXPENDITURE POLICIES ARE FOLLOWED TO ENSURE APPROVALS AND CONTROLS ARE MAINTAINED TO DISBURSE GRANT FUNDS INTERNATIONALLY. THE GRANT PROVIDED TO EUROPE IS PART OF A BONE MARROW /STEM CELL TRANSPLANT RESEARCH SCHOLAR PROGRAM. THE GRANTEES ARE REQUIRED ON A BI-ANNUAL BASIS TO SUBMIT DETAILED PROGRESS REPORTS TO NMDP THAT OUTLINE THE USE OF FUNDS. THE PAYMENTS ARE MADE TO THE INSTITUTION THAT THE SCHOLAR IS CONDUCTING RESEARCH AT AS AN ADDITIONAL PRECAUTION THAT THE FUNDS ARE USED FOR THEIR INTENDED PURPOSE. Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual Schedule F, Part II, Line 1 Method used to account for expenditures on org's financial statements EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual Schedule F, Part III Method used to account for expenditures on org's financial statements NORTH AMERICA (CANADA & MEXICO ONLY) -Accrual X X X X X X true THE STELTER COMPANY 10435 NEW YORK AVE DES MOINES IA 50322 Gift & Newsletter Consultant false 0 41207 -41207 MMS USA INVESTMENTS INC DBA EPSILON AGENCY LLC 35 WEST WACKER DRIVE chicago IL 60601 Fundraising Consulting false 0 556422 -556422 GOODUNITED 796 MEETING STREET CHARLESTON SC 29403 Fundraising Consulting false 0 14400 -14400 0 612029 -612029 CA FL GA AL HI IL KS KY MD MA MI MN MS NH NJ NM NY NC OR PA RI SC TN UT VA AR WV WI Minneapolis Gala 1220477 1126352 94125 1963 116102 75216 120066 32409 New York Gala 445155 408905 36250 140423 101730 23922 2 593444 559813 33631 29244 43713 44440 19875 2259076 2095070 164006 1963 285769 118929 266236 76206 749103 -585097 35610 5054 230 false 35610 5054 230 MN true false true false 0.0 1.0 Joy King 500 N 5th Street Minneapolis MN 55401 false Stacey Chase 0 Gaming coordinator X false 0 Schedule G, Part I, Line 2b(v) THE GROSS RECEIPTS FROM THE ACTIVITIES THAT PROFESSIONAL FUNDRAISERS ASSIST THE ORGANIZATION ON ARE NOT ABLE TO BE SEPARATELY REPORTED AS THE WORK AIDS IN MANY FUNDRAISING INITIATIVES THROUGHOUT THE FISCAL YEAR. Schedule G, Part III, Line 16 OTHER GAMING MANAGER INCLUDES AMANDA ALBERTSON WHO OBTAINS LICENSES AND MANAGES THE PLANNING AND EXECUTION OF RAFFLES. true National Marrow Donor Program 500 N 5th Street Minneapolis MN 55401 840865803 501(C)(3) 749549 Various NMDP Programs National Marrow Donor Program 500 N 5th Street Minneapolis MN 55401 840865803 501(C)(3) 45448 CLINICAL TRIALS SUPPORT National Marrow Donor Program 500 N 5th Street Minneapolis MN 55401 840865803 501(C)(3) 676771 DONOR RECRUITMENT National Marrow Donor Program 500 N 5th Street Minneapolis MN 55401 840865803 501(C)(3) 526303 Mexico PATIENT ASSISTANCE National Marrow Donor Program 500 N 5th Street Minneapolis MN 55401 840865803 501(C)(3) 1090876 RESEARCH National Marrow Donor Program 500 N 5th Street Minneapolis MN 55401 840865803 501(C)(3) 350672 PROGRAM SUPPORT - SALARY Fred Hutchinson Cancer Research MAILSTOP LF-272 PO BOX 19024 SEATTLE WA 19024 237156071 501(C)(3) 240000 RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER 633 3RD AVENUE 4TH FLOOR NEW YORK NY 10017 131924236 501(C)(3) 80000 RESEARCH UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BOULEVARD HOUSTON TX 77030 746001118 501(C)(3) 120000 RESEARCH UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL PO BOX 402420 ATLANTA GA 30384 566001393 501(C)(3) 80000 RESEARCH UNIVERSITY OF ALABAMA 701 20TH STREET SOUTH BIRMINGHAM AL 35294 630649108 501(C)(3) 80000 RESEARCH WASHINGTON UNIVERSITY OF ST LOUIS 600 SOUTH EUCLID AVENUE ST LOUIS MO 63110 430654872 501(C)(3) 80000 RESEARCH BAYLOR COLLEGE OF MEDICINE PO BOX 4803 HOUSTON TX 77210 741613878 501(C)(3) 36000 RESEARCH INDIANA UNIVERSITY 1024 EAST 3RD ST ROOM 132 BLOOMINGTON IN 47405 356001673 501(C)(3) 120000 RESEARCH MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 21140 042697983 501(C)(3) 80000 RESEARCH JULIE ROGERS GIFT OF LIFE PROGRAM 2390 DOWLEN ROAD BEAUMONT TX 77706 760550450 501(C)(3) 33000 VARIOUS PROGRAM LIFESHARE BLOOD CENTERS 8910 LINWOOD AVENUE SHREVEPORT LA 71106 720511367 501(C)(3) 33000 VARIOUS PROGRAM 17 0 Patient Transplant Assistance 2361 4308107 Clinical Trials Assistance 176 376250 Patient Typing & Search Assistance 248 136284 Donor Assistance 493 428639 Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds. Procedure for monitoring the use of grant funds inside the U.S. Patient assistance grants are awarded through NMDP Foundation. Patients apply for pre and post-transplant support grants through the online application. These applications and patient assistance are tracked in the Oracle custom-built module and monitored by the patient outcomes and experiences team, a Department within NMDP. This team reviews applications weekly and determines assistance needs based on published criteria, all with the goal to equitably administer to help patients overcome barriers before and after transplant. Search assistance funds are awarded to cover uninsured donor search costs. When a transplant center (organizations) receives an insurance denial letter for donor search costs they are able to complete an application that includes providing a copy of the denial letter. If approved the grant is then distributed directly to the transplant center. All other patient assistance grants are awarded to the applicant based on financial need and are used to cover such items as uninsured costs, co-pays, food, lodging, and ground transportation. Payments are made directly to the patient/applicant (individual). Donor assistance checks are also awarded to the applicant based on financial needs and are used to offset having to take unpaid time off from work in order to donate life-saving cells. Payments are made directly to the donor (individual). false false false false false false false true false AMY RONNEBERG Chief Executive Officer 0 726731 0 738407 0 21988 0 250662 0 22 0 1737810 0 127781 gina graves former officer 0 219405 0 127022 0 12026 0 25790 0 10564 0 394807 0 15827 jeffrey chell former officer 0 0 0 0 0 100002 0 0 0 0 0 100002 0 0 KRISTA DUSIL CHIEF FINANCIAL OFFICER 0 331370 0 221373 0 12271 0 52262 0 26655 0 643931 0 0 Joy King CHIEF ADVANCEMENT OFFICER 117772 176658 103150 154725 4379 6568 35888 53831 9554 14331 270743 406113 15863 23795 Todd Peterson VICE PRESIDENT, ADVANCEMENT 182331 0 43523 0 5344 0 39143 0 26673 0 297014 0 0 0 Angie Fitzgerald SENIOR DIRECTOR, CORPORATE PARTNERSHIPS 142736 0 42795 0 1219 0 30217 0 25938 0 242905 0 0 0 Daniel LEE DIRECTOR, MAJOR AND PLANNED GIFTS 136927 0 21815 0 1137 0 12461 0 33388 0 205728 0 0 0 Alex Mensing DIRECTOR, BENEFACTOR ENGAGEMENT & MARKETING 122780 0 35320 0 1043 0 12802 0 29078 0 201023 0 0 0 Jacqueline Chandonnet DIRECTOR, DEVELOPMENT 150144 0 9346 0 1488 0 12207 0 9345 0 182530 0 0 0 Schedule J, Part I, Line 3 Arrangement used to establish the top management official's compensation METHODS USED BY RELATED ORGANIZATION NMDP TO ESTABLISH TOP MANAGEMENT OFFICIALS' COMPENSATION: COMPENSATION COMMITTEE, INDEPENDENT COMPENSATION CONSULTANT, COMPENSATION SURVEY OR STUDY, AND APPROVAL BY THE COMPENSATION COMMITTEE. PLEASE ALSO SEE NARRATIVE ON SCHEDULE O, FOR FORM 990, PART VI, SECTION B, LINE 15A. Schedule J, Part I, Line 7 THE ORGANIZATION OFFERS AN ANNUAL INCENTIVE PLAN (AIP) TO ALL EMPLOYEES FOR THE CONTRIBUTIONS THEY MAKE TO THE ORGANIZATION'S RESULTS. AIP AWARDS ARE DETERMINED AS PART OF A FORMULA UTILIZING AN EMPLOYEE'S BASE PAY, THE EMPLOYEE'S AIP TARGET PERCENTAGE, AND THE ORGANIZATION'S PERFORMANCE. AIP AWARDS ARE SUBJECT TO EXECUTIVE TEAM APPROVAL AND TO ACHIEVING ESTABLISHED PERFORMANCE REQUIREMENTS. THE ORGANIZATION OFFERS A LONG-TERM INCENTIVE PLAN (LTIP) TO ELIGIBLE SENIOR LEADERSHIP EMPLOYEES. THE VARIABLE INCENTIVE COMPENSATION PLAN IS MEANT TO LINK SENIOR LEADER COMPENSATION TO ACHIEVEMENT OF LONG-TERM PERFORMANCE RESULTS AND TO ASSIST THE ORGANIZATION IN ATTRACTING AND RETAINING SENIOR LEADERS BY PROVIDING MISSION-BASED LONG-TERM INCENTIVES AND REWARDS FOR SUPERIOR PERFORMANCE. LTIP AWARDS ARE DETERMINED AS PART OF A FORMULA UTILIZING AN EMPLOYEE'S BASE SALARY IN EFFECT ON THE LAST DAY OF THE PERFORMANCE PERIOD, THE EMPLOYEE'S LTIP TARGET PERCENTAGE ESTABLISHED AT THE BEGINNING OF EACH PERFORMANCE PERIOD, AND THE OPERATING PERFORMANCE INDEX RESULTS FOR THE PERFORMANCE PERIOD. THE AWARD IS SUBJECT TO ACHIEVING ESTABLISHED PERFORMANCE REQUIREMENTS. LTIP AWARDS REPORTED AS AN EMPLOYEE'S DEFERRED COMPENSATION IN PRIOR YEARS AND PAID IN THE CURRENT YEAR ARE REPORTED IN COLUMN (F) AND INCLUDED IN COLUMN (B)(II) FOR THE CURRENT YEAR. X 9 98685 Market value X auction items 183 141285 Market value X Advertising Time and Media Space 1 121770 Market value 0 false true false Schedule M, Part I Explanations of reporting method for number of contributions Other - auction items NMDP Foundation uses the number of contributions as the method for determine the amount in column (b). Form 990, Part III, Line 1 CONTINUED AT NMDP, WE BELIEVE EACH OF US HOLDS THE KEY TO CURING BLOOD CANCERS AND DISORDERS. AS A GLOBAL NONPROFIT LEADER IN CELL THERAPY, NMDP CREATES ESSENTIAL CONNECTIONS BETWEEN RESEARCHERS AND SUPPORTERS TO INSPIRE ACTION AND ACCELERATE INNOVATION TO FIND LIFE-SAVING CURES. WITH THE HELP OF BLOOD STEM DONORS FROM THE WORLD'S MOST DIVERSE REGISTRY AND OUR EXTENSIVE NETWORK OF TRANSPLANT PARTNERS, PHYSICIANS AND CAREGIVERS, WE'RE EXPANDING ACCESS TO TREATMENT SO THAT EVERY PATIENT CAN RECEIVE THEIR LIFE-SAVING CELL THERAPY. NMDP. FIND CURES. SAVE LIVES. OUR MISSION: WE SAVE LIVES THROUGH CELL THERAPY. OUR VISION: CREATE A WORLD WHERE EVERY PATIENT CAN RECEIVE THEIR LIFE-SAVING CELL THERAPY. THE NMDP FOUNDATION RAISES FUNDS FOR THREE PROGRAMS CRITICAL TO OUR LIFE-SAVING MISSION: TRANSPLANT RESEARCH, PATIENT FINANCIAL ASSISTANCE AND DONOR RECRUITMENT. SOME OF THE LIFE-CHANGING WORK THAT WE'RE DOING IS SOLEY FUNDING BY OUR COMMUNITY OF SUPPORTERS. WE CONDUCT RESEARCH THROUGH OUR RESEARCH PROGRAM, CIBMTR (CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH) IN COLLABORATION WITH THE MEDICAL COLLEGE OF WISCONSIN. OUR RESEARCH LEADS TO MORE LIVES SAVED AND AN ENRICHED QUALITY OF LIFE FOR THOUSANDS OF PATIENTS. THROUGH THE NMDP AMY STRELZER MANASEVIT RESEARCH PROGRAM AND OTHER RESEARCH GRANTS, OUTSTANDING EARLY-CAREER RESEARCHERS ARE DOING INNOVATIVE WORK TO FIND SOLUTIONS TO THE COMPLICATIONS THAT CAN ARISE AFTER TRANSPLANT. THEY'RE DEVELOPING TREATMENT APPROACHES THAT WILL HELP THE NEXT GENERATION OF TRANSPLANT PATIENTS LIVE LONGER, HEALTHIER LIVES. PATIENT FINANCIAL ASSISTANCE HELPS COVER TRANSPLANT-RELATED COSTS NOT COVERED BY INSURANCE THAT CAUSE SIGNIFICANT HARDSHIP OR EVEN PREVENT PATIENTS FROM MOVING FORWARD WITH TRANSPLANT. COSTS LIKE TRANSPORTATION, LODGING, LOST WAGES AND PRESCRIPTIONS. NMDP CONNECTS PATIENTS WITH A MATCHING, UNRELATED DONOR, A SELFLESS STRANGER WHO CAN STEP UP AND DONATE THEIR HEALTHY BLOOD STEM CELLS TO GIVE THEM THE CHANCE AT A LIFE-SAVING TRANSPLANT. Form 990, Part III, Line 4d Description of other program services (Expenses $ 7,133,754 including grants of $ 1,647,306) NMDP FOUNDATION PARTNERS WITH NMDP TO ADVANCE VARIOUS INITIATIVES TIED TO THE SHARED MISSION. THESE PROGRAMS INCLUDE: NMDP PROVIDES COMPREHENSIVE EDUCATION AND SUPPORT SERVICES TO PATIENTS AND THEIR FAMILIES THROUGH ONE-ON-ONE NAVIGATION SUPPORT, VIDEO, PRINTED, AND DIGITAL EDUCATION RESOURCES, COUNSELING, NMDP PEER CONNECT PROGRAM, NMDP SURVIVORSHIP PROGRAM, NMDP SICKLE CELL WARRIOR PROGRAM, AND THE JASON CARTER CLINICAL TRIALS SEARCH AND SUPPORT PROGRAM, WHICH HELPS PATIENTS WITH LIFE-THREATENING BLOOD DISORDERS FIND CLINICAL TRIALS. NMDP Foundation RAISES FUNDS TO SUPPORT THESE CRITICAL SERVICES. NMDP ALLOCATES COMPENSATION AND BENEFITS AND OCCUPANCY COSTS TO PROGRAMS BASED ON EMPLOYEE RESPONSIBILITIES. Form 990, Part VI, Line 4 Significant changes to organizational documents The NMDP Foundation Board of Directors and NMDP Board of Directors approved a name change from Be The Match Foundation to NMDP Foundation. The NMDP Foundation Articles of Incorporation were revised for the name change, effective December 1, 2023. In addition to administrative changes, the NMDP Foundation Articles of Incorporation dissolution article was revised to clarify that the Member (as identified within the Bylaws of the NMDP Foundation) receives the asset distribution upon dissolution, if the Member is a 501(c)(3) at that time. Form 990, Part VI, Line 6 Classes of members or stockholders MEMBERS OR STOCKHOLDERS: NMDP IS THE SOLE CORPORATE MEMBER OF NMDP Foundation. Form 990, Part VI, Line 7a Members or stockholders electing members of governing body MEMBERS OR STOCKHOLDERS WHO MAY ELECT GOVERNING BODY: THE NMDP BOARD ELECTS THE BOARD OF DIRECTORS OF NMDP Foundation. Form 990, Part VI, Line 7b Decisions requiring approval by members or stockholders MEMBERS OR STOCKHOLDERS WHO MAY APPROVE DECISIONS: THE NMDP BOARD APPROVES THE ACTIONS OF NMDP Foundation. Form 990, Part VI, Line 11b Review of form 990 by governing body Form 990 review process: The organization contracted with the outside public accounting firm, Baker Tilly, to prepare the Form 990. Preparing the details and supporting reports for the return is a collaborative effort among a small group of individuals in the financial reporting & compliance area of finance, internal audit and human resources. Once a draft is received back from Baker Tilly, it is reviewed by the team that pulled the details together, Director, Finance and Corporate Controller, Chief Advance Office and Chief Financial Officer. NMDP Chief Administrative Officer also review the governance sections. A copy of the return is provided to the organization's Audit & Finance Committee and board of directors prior to filing. Form 990, Part VI, Line 12c Conflict of interest policy The Conflict-of-Interest Policy states the following: "The existence of an actual or potential conflict of interest turns on the specific facts and circumstances in each case. If a member has an interest which may conflict with those of the Organizations, he or she must immediately disclose the matters and discuss them fully and frankly with the applicable Organization's full Board or its Executive Committee, as set forth in detail below. A Member must not participate in any matter in which that Member may have an actual or potential conflict of interest without the express approval of the applicable Organization's Board of Directors or Executive Committee of the Board of Directors (Executive Committee). All Members must disclose to the applicable Organization's Board of Directors or Executive Committee all conflicts of interest and reportable relationships and must annually complete and submit the Conflict-of-Interest Questionnaire which is required by this Policy. Whenever in the course of events a Member's circumstances change such that the Member knows or has reason to believe that the Member may have an actual or perceived conflict of interest, such Member shall promptly disclose the potential conflict to the applicable Organization's Board of Directors or Executive Committee. For the purposes of this Article, a Member may formally disclose a conflict or reportable relationship to the NMDP Chief Executive Officer (CEO), the Chief Advancement Officer, or the NMDP Chief Administrative Officer (CAO), as applicable, who shall inform the applicable Organization's Board of Directors or Executive Committee for resolution. As noted herein, if the potential conflict involves a Director or Committee Member, that Director or Committee Member shall not participate in or vote upon such matters until the question of the existence of the conflict of interest has been resolved in accordance with this Policy. Likewise, an officer or key employee may not become substantially involved in decision-making involving any covered litigation, contract or transaction until the resolution of the matter in accordance with this Policy." Form 990, Part VI, Line 15a Process to establish compensation of top management official Process for determining compensation: THE CHIEF ADVANCEMENT OFFICER REPORTS DIRECTLY TO THE NMDP CHIEF EXECUTIVE OFFICER (CEO) AND IS CONSIDERED A KEY EMPLOYEE PER IRS DEFINITION. THE COMPENSATION OF THE CHIEF ADVANCEMENT OFFICER IS REVIEWED, EVALUATED, AND SET IN ACCORDANCE WITH THE NMDP BYLAWS AND COMPENSATION COMMITTEE CHARTER. THE NMDP BYLAWS STATE: "THE COMPENSATION COMMITTEE SHALL BE COMPRISED ONLY OF VOTING DIRECTORS AND SHALL INCLUDE THE CHAIR OF THE BOARD AND AT LEAST ONE (1) NON-OFFICER BOARD MEMBER AS VOTING COMMITTEE MEMBERS. THE COMPENSATION COMMITTEE SHALL REVIEW AND EVALUATE THE OVERALL COMPENSATION AND BENEFIT STRUCTURE OF THE CORPORATION AND SHALL HAVE SUCH OTHER AUTHORITY AND RESPONSIBILITIES AS SET FORTH IN THE COMPENSATION COMMITTEE CHARTER." THE COMPENSATION COMMITTEE CHARTER STATES: "THE COMMITTEE SHALL REVIEW AND EVALUATE THE OVERALL COMPENSATION AND BENEFIT STRUCTURE OF THE CORPORATION AND APPROVE AND ADOPT A COMPENSATION PHILOSOPHY AND PRINCIPLES CONSISTENT WITH THE CORPORATION'S NON-FOR-PROFIT STATUS (THE "COMPENSATION PHILOSOPHY AND PRINCIPLES"). THE COMMITTEE SHALL CONDUCT THE CHIEF EXECUTIVE OFFICER ("CEO") PERFORMANCE EVALUATION. THE COMMITTEE SHALL MAKE CEO TOTAL COMPENSATION AND BENEFIT RECOMMENDATIONS TO THE EXECUTIVE COMMITTEE, CONSISTENT WITH THE COMPENSATION PHILOSOPHY AND PRINCIPLES. IN MAKING COMPENSATION AND BENEFIT RECOMMENDATIONS FOR THE CEO, THE COMMITTEE SHALL UTILIZE, AMONG OTHER THINGS, COMPARABILITY DATA FOR COMPLIANCE WITH IRS INTERMEDIATE SANCTION PROVISIONS SO AS TO ALLOW THE CORPORATION TO TAKE ADVANTAGE OF THE REBUTTABLE PRESUMPTION OF REASONABLENESS. ON A PERIODIC BASIS, THE COMMITTEE SHALL OBTAIN COMPARABILITY DATA FROM AN INDEPENDENT COMPENSATION CONSULTANT. IN ADDITION, THE COMMITTEE SHALL ADVISE THE CEO IN HIS/HER EVALUATION OF AND DECISIONS REGARDING THE COMPENSATION OF AND BENEFITS FOR SENIOR CORPORATION EMPLOYEES, AS WELL AS THE PRESIDENT (OR EQUIVALENT LEADER) OF ANY SUBSIDIARY OF THE CORPORATION REPORTING TO THE CEO (TOGETHER, "SENIOR LEADERSHIP"). IN ADVISING THE CEO IN MAKING HIS/HER COMPENSATION AND BENEFIT DECISIONS FOR SENIOR LEADERSHIP, THE COMMITTEE SHALL ENSURE THAT SUCH DECISIONS ARE CONSISTENT WITH THE COMPENSATION PHILOSOPHY AND PRINCIPLES, AND UTILIZE, AMONG OTHER THINGS, COMPARABILITY DATA FOR COMPLIANCE WITH IRS INTERMEDIATE SANCTION PROVISIONS. IF DECISIONS PROPOSED BY THE CEO ARE OUTSIDE THE PARAMETERS OF THE COMPENSATION PHILOSOPHY AND PRINCIPLES, THE CEO MUST OBTAIN THE COMMITTEE'S APPROVAL PRIOR TO IMPLEMENTATION." Form 990, Part VI, Line 19 Required documents available to the public How documents are made available to the public: The conflict of interest policy, articles of incorporation and consolidated audited financial statements and additional consolidating information are all made available to the public upon request. The consolidated audited financial statements are also available on our website. Summary financial statements are also included in our annual report, which is mailed to key stakeholders and posted on our website. Additionally, articles of incorporation are available at the MN office of the secretary of state, and consolidated audited financial statements may be obtained at the MN office of the attorney general. Form 990, Part XI, Line 9 Other changes in net assets or fund balances bad debt allowance - -40000; Form 990, Part XII, Line 2c THE ORGANIZATION HAS NEITHER CHANGED ITS OVERSIGHT PROCESS OR SELECTION PROCESS DURING THE TAX YEAR. Form 990, page 1, item B: THE RETURN FOR THE CURRENT YEAR IS BEING AMENDED TO REFLECT THE FOLLOWING: 1. FORM 990, PART VII, SECTION A, LINES 1A, 1B, AND 1D COLUMN (F) ARE REVISED TO REFLECT THE ACCURATE COMPENSATION REPORTING FOR THE FISCAL YEAR. AFTER FILING FORM 990, IT WAS DISCOVERED THE ORGANIZATION ERRONEOUSLY FAILED TO INCLUDE IN COLUMN (F) THE AMOUNT EARNED BY ELIGIBLE INDIVIDUALS UNDER THE ORGANIZATION'S LONG-TERM INCENTIVE PLAN. 2. SCHEDULE J PART II, COLUMN (C), COLUMN (E), AND COLUMN (F) ARE REVISED TO REFLECT THE ACCURATE REPORTING OF COMPENSATION AND DEFERRED COMPENSATION FOR THE PERIOD. AMOUNTS DEFERRED AND PAID UNDER THE ORGANIZATION'S LONG-TERM INCENTIVE PLAN WERE ERRONEOUSLY EXCLUDED FROM THE FILING. THIS AMENDMENT CORRECTS THE INADVERTENT ERROR. SEE SCHEDULE J PART III LINE 7 FOR ADDITIONAL DISCLOSURES. NATIONAL MARROW DONOR PROGRAM 500 N 5TH STREET MINNEAPOLIS MN 554011206 840865803 TRANSPLANTS CO 501(c)(3) 10 NA false BE THE MATCH MX AC VERACRUZ AV 93 101 PISO CUIDAD DE MEXICO CONDESA MX RECRUITMENT MX NMDP false NMDP AUXILIARY SERVICES LLC 500 N 5TH ST MINNEAPOLIS MN 554011206 811248190 CELLULAR THERAPY MN NA C Corporation false CLEAR INSURANCE LTD 62 FORUM LN 3RD FL PO BOX 30600 GRAND CAYMAN CJ KY11203 840865803 CAPTIVE INSURANCE CJ NA C Corporation false false true true false false false false false false false false false false true true false false false false